AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. GSK
  4. [6-K] GSK plc American Current Report (Foreign Issuer)

[6-K] GSK plc American Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
Rhea-AI Filing Summary

GSK plc filed a Form 6-K detailing a routine share repurchase executed on 31 July 2025 under its June-2025 non-discretionary buy-back mandate.

  • Shares bought: 474,100 ordinary shares (nominal 31录 p).
  • Price range: 1,404.50鈥�1,461.00&苍产蝉辫;骋叠辫; VWAP 1,423.11 GBp.
  • Cumulative purchases since 4 June 2025: 18,910,038 shares.

The shares will be held in treasury, increasing the treasury balance to 237,044,421. Shares in issue (excluding treasury) now total 4,078,340,989, establishing the new denominator for voting-rights disclosures. Treasury stock represents 5.81 % of total voting rights.

No operational, earnings or guidance updates were provided; the filing primarily fulfils UK DTR 5.5.1R disclosure requirements.

GSK plc ha depositato un Modulo 6-K che dettaglia un riacquisto di azioni di routine eseguito il 31 luglio 2025 nell'ambito del mandato di riacquisto non discrezionale di giugno 2025.

  • Azioni acquistate: 474.100 azioni ordinarie (valore nominale 31录 p).
  • Fascia di prezzo: 1.404,50鈥�1.461,00 GBp; prezzo medio ponderato (VWAP) 1.423,11 GBp.
  • Acquisti cumulativi dal 4 giugno 2025: 18.910.038 azioni.

Le azioni saranno detenute in tesoreria, portando il saldo di tesoreria a 237.044.421. Le azioni in circolazione (escluse quelle in tesoreria) ammontano ora a 4.078.340.989, stabilendo il nuovo denominatore per le comunicazioni sui diritti di voto. Le azioni in tesoreria rappresentano il 5,81% dei diritti di voto totali.

Non sono state fornite aggiornamenti operativi, sugli utili o sulle previsioni; il deposito serve principalmente a soddisfare i requisiti di informativa del Regolamento UK DTR 5.5.1R.

GSK plc present贸 un Formulario 6-K detallando una recompra rutinaria de acciones ejecutada el 31 de julio de 2025 bajo su mandato de recompra no discrecional de junio de 2025.

  • Acciones compradas: 474,100 acciones ordinarias (valor nominal 31录 p).
  • Rango de precios: 1,404.50鈥�1,461.00 GBp; VWAP 1,423.11 GBp.
  • Compras acumuladas desde el 4 de junio de 2025: 18,910,038 acciones.

Las acciones se mantendr谩n en tesorer铆a, aumentando el saldo a 237,044,421. Las acciones en circulaci贸n (excluyendo tesorer铆a) ahora suman 4,078,340,989, estableciendo el nuevo denominador para las divulgaciones de derechos de voto. Las acciones en tesorer铆a representan el 5.81% de los derechos de voto totales.

No se proporcionaron actualizaciones operativas, de ganancias ni de previsiones; la presentaci贸n cumple principalmente con los requisitos de divulgaci贸n del UK DTR 5.5.1R.

GSK plc電� 2025雲� 7鞗� 31鞚检棎 鞁滍枆霅� 2025雲� 6鞗� 牍勳灛霟夓爜 鞛愳偓欤� 毵れ瀰 氇呺牴鞐� 霐半ジ 鞝曣赴 鞛愳偓欤� 毵れ瀰 雮挫棴鞚� 雼挫潃 6-K 鞏戩嫕鞚� 鞝滌稖頄堨姷雼堧嫟.

  • 毵れ瀰 欤检嫕 靾�: 474,100 氤错喌欤� (鞎‰┐臧� 31录 p).
  • 臧�瓴� 氩旍渼: 1,404.50鈥�1,461.00 GBp; VWAP 1,423.11 GBp.
  • 2025雲� 6鞗� 4鞚茧秬韯� 雸勳爜 毵れ瀰 欤检嫕 靾�: 18,910,038 欤�.

毵れ瀰霅� 欤检嫕鞚� 鞛愳偓欤茧 氤挫湢霅橃柎 鞛愳偓欤� 鞛旉碃臧� 237,044,421搿� 歃濌皜頃╇媹雼�. 鞛愳偓欤茧ゼ 鞝滌櫢頃� 氚滍枆 欤检嫕 靾橂姅 順勳灛 4,078,340,989欤茧, 鞚措姅 鞚橁舶甓� 瓿奠嫓毳� 鞙勴暅 靸堧鞖� 攵勲臧� 霅╇媹雼�. 鞛愳偓欤茧姅 鞝勳泊 鞚橁舶甓岇潣 5.81%毳� 彀頃╇媹雼�.

鞖挫榿, 靾橃澋 霕愲姅 臧�鞚措崢鞀� 鞐呺嵃鞚错姼電� 鞝滉车霅橃 鞎婌晿鞙茧┌, 鞚措矆 鞝滌稖鞚� 欤茧 鞓侁淡 DTR 5.5.1R 瓿奠嫓 鞖旉贝鞚� 於╈”頃橁赴 鞙勴暅 瓴冹瀰雼堧嫟.

GSK plc a d茅pos茅 un formulaire 6-K d茅taillant un rachat d'actions de routine effectu茅 le 31 juillet 2025 dans le cadre de son mandat de rachat non discr茅tionnaire de juin 2025.

  • Actions achet茅es : 474 100 actions ordinaires (valeur nominale 31录 p).
  • Fourchette de prix : 1 404,50鈥�1 461,00 GBp ; VWAP 1 423,11 GBp.
  • Achats cumul茅s depuis le 4 juin 2025 : 18 910 038 actions.

Les actions seront d茅tenues en tr茅sorerie, portant le solde de tr茅sorerie 脿 237 044 421. Les actions en circulation (hors tr茅sorerie) totalisent d茅sormais 4 078 340 989, 茅tablissant le nouveau d茅nominateur pour les divulgations des droits de vote. Le stock en tr茅sorerie repr茅sente 5,81 % des droits de vote totaux.

Aucune mise 脿 jour op茅rationnelle, sur les r茅sultats ou les pr茅visions n鈥檃 茅t茅 fournie ; le d茅p么t r茅pond principalement aux exigences de divulgation du r猫glement britannique DTR 5.5.1R.

GSK plc reichte ein Formular 6-K ein, das einen routinem盲脽igen Aktienr眉ckkauf am 31. Juli 2025 im Rahmen des nicht diskretion盲ren R眉ckkaufmandats von Juni 2025 beschreibt.

  • Gekaufte Aktien: 474.100 Stammaktien (Nennwert 31录 p).
  • Preisspanne: 1.404,50鈥�1.461,00 GBp; VWAP 1.423,11 GBp.
  • Kumulative K盲ufe seit dem 4. Juni 2025: 18.910.038 Aktien.

Die Aktien werden im Tresorbestand gehalten, wodurch sich der Tresorbestand auf 237.044.421 erh枚ht. Die ausstehenden Aktien (ohne Tresorbestand) belaufen sich nun auf 4.078.340.989 und bilden die neue Basis f眉r die Offenlegung der Stimmrechte. Der Tresorbestand entspricht 5,81 % der Gesamtstimmrechte.

Es wurden keine operativen, Ergebnis- oder Prognoseaktualisierungen bereitgestellt; die Einreichung dient haupts盲chlich der Erf眉llung der Offenlegungspflichten gem盲脽 UK DTR 5.5.1R.

Positive
  • Continued execution of the authorised share-buyback programme demonstrates confidence in cash flow generation and provides incremental EPS accretion.
Negative
  • Repurchased volume is immaterial versus 4.08 bn shares outstanding, limiting near-term impact on valuation or ownership structure.

Insights

TL;DR: Minor buyback disclosure; immaterial to valuation but signals ongoing capital return.

Today鈥檚 Form 6-K shows GSK purchased 474 k shares鈥攔oughly 0.01 % of the 4.08 bn float鈥攁t a 1,423 p VWAP. While the absolute cash outlay (~拢6.7 m) is modest, the cumulative 18.9 m shares bought since 4 Jun equals ~0.46 % of shares outstanding, offering a marginal tail-wind to EPS and offsetting dilution from incentive schemes. Balance-sheet capacity remains ample; net debt/EBITDA ended 2024 at 1.3脳, so repurchases should not constrain pipeline funding. From a market perspective the event is not impactful; it confirms program execution rather than changing forward fundamentals.

GSK plc ha depositato un Modulo 6-K che dettaglia un riacquisto di azioni di routine eseguito il 31 luglio 2025 nell'ambito del mandato di riacquisto non discrezionale di giugno 2025.

  • Azioni acquistate: 474.100 azioni ordinarie (valore nominale 31录 p).
  • Fascia di prezzo: 1.404,50鈥�1.461,00 GBp; prezzo medio ponderato (VWAP) 1.423,11 GBp.
  • Acquisti cumulativi dal 4 giugno 2025: 18.910.038 azioni.

Le azioni saranno detenute in tesoreria, portando il saldo di tesoreria a 237.044.421. Le azioni in circolazione (escluse quelle in tesoreria) ammontano ora a 4.078.340.989, stabilendo il nuovo denominatore per le comunicazioni sui diritti di voto. Le azioni in tesoreria rappresentano il 5,81% dei diritti di voto totali.

Non sono state fornite aggiornamenti operativi, sugli utili o sulle previsioni; il deposito serve principalmente a soddisfare i requisiti di informativa del Regolamento UK DTR 5.5.1R.

GSK plc present贸 un Formulario 6-K detallando una recompra rutinaria de acciones ejecutada el 31 de julio de 2025 bajo su mandato de recompra no discrecional de junio de 2025.

  • Acciones compradas: 474,100 acciones ordinarias (valor nominal 31录 p).
  • Rango de precios: 1,404.50鈥�1,461.00 GBp; VWAP 1,423.11 GBp.
  • Compras acumuladas desde el 4 de junio de 2025: 18,910,038 acciones.

Las acciones se mantendr谩n en tesorer铆a, aumentando el saldo a 237,044,421. Las acciones en circulaci贸n (excluyendo tesorer铆a) ahora suman 4,078,340,989, estableciendo el nuevo denominador para las divulgaciones de derechos de voto. Las acciones en tesorer铆a representan el 5.81% de los derechos de voto totales.

No se proporcionaron actualizaciones operativas, de ganancias ni de previsiones; la presentaci贸n cumple principalmente con los requisitos de divulgaci贸n del UK DTR 5.5.1R.

GSK plc電� 2025雲� 7鞗� 31鞚检棎 鞁滍枆霅� 2025雲� 6鞗� 牍勳灛霟夓爜 鞛愳偓欤� 毵れ瀰 氇呺牴鞐� 霐半ジ 鞝曣赴 鞛愳偓欤� 毵れ瀰 雮挫棴鞚� 雼挫潃 6-K 鞏戩嫕鞚� 鞝滌稖頄堨姷雼堧嫟.

  • 毵れ瀰 欤检嫕 靾�: 474,100 氤错喌欤� (鞎‰┐臧� 31录 p).
  • 臧�瓴� 氩旍渼: 1,404.50鈥�1,461.00 GBp; VWAP 1,423.11 GBp.
  • 2025雲� 6鞗� 4鞚茧秬韯� 雸勳爜 毵れ瀰 欤检嫕 靾�: 18,910,038 欤�.

毵れ瀰霅� 欤检嫕鞚� 鞛愳偓欤茧 氤挫湢霅橃柎 鞛愳偓欤� 鞛旉碃臧� 237,044,421搿� 歃濌皜頃╇媹雼�. 鞛愳偓欤茧ゼ 鞝滌櫢頃� 氚滍枆 欤检嫕 靾橂姅 順勳灛 4,078,340,989欤茧, 鞚措姅 鞚橁舶甓� 瓿奠嫓毳� 鞙勴暅 靸堧鞖� 攵勲臧� 霅╇媹雼�. 鞛愳偓欤茧姅 鞝勳泊 鞚橁舶甓岇潣 5.81%毳� 彀頃╇媹雼�.

鞖挫榿, 靾橃澋 霕愲姅 臧�鞚措崢鞀� 鞐呺嵃鞚错姼電� 鞝滉车霅橃 鞎婌晿鞙茧┌, 鞚措矆 鞝滌稖鞚� 欤茧 鞓侁淡 DTR 5.5.1R 瓿奠嫓 鞖旉贝鞚� 於╈”頃橁赴 鞙勴暅 瓴冹瀰雼堧嫟.

GSK plc a d茅pos茅 un formulaire 6-K d茅taillant un rachat d'actions de routine effectu茅 le 31 juillet 2025 dans le cadre de son mandat de rachat non discr茅tionnaire de juin 2025.

  • Actions achet茅es : 474 100 actions ordinaires (valeur nominale 31录 p).
  • Fourchette de prix : 1 404,50鈥�1 461,00 GBp ; VWAP 1 423,11 GBp.
  • Achats cumul茅s depuis le 4 juin 2025 : 18 910 038 actions.

Les actions seront d茅tenues en tr茅sorerie, portant le solde de tr茅sorerie 脿 237 044 421. Les actions en circulation (hors tr茅sorerie) totalisent d茅sormais 4 078 340 989, 茅tablissant le nouveau d茅nominateur pour les divulgations des droits de vote. Le stock en tr茅sorerie repr茅sente 5,81 % des droits de vote totaux.

Aucune mise 脿 jour op茅rationnelle, sur les r茅sultats ou les pr茅visions n鈥檃 茅t茅 fournie ; le d茅p么t r茅pond principalement aux exigences de divulgation du r猫glement britannique DTR 5.5.1R.

GSK plc reichte ein Formular 6-K ein, das einen routinem盲脽igen Aktienr眉ckkauf am 31. Juli 2025 im Rahmen des nicht diskretion盲ren R眉ckkaufmandats von Juni 2025 beschreibt.

  • Gekaufte Aktien: 474.100 Stammaktien (Nennwert 31录 p).
  • Preisspanne: 1.404,50鈥�1.461,00 GBp; VWAP 1.423,11 GBp.
  • Kumulative K盲ufe seit dem 4. Juni 2025: 18.910.038 Aktien.

Die Aktien werden im Tresorbestand gehalten, wodurch sich der Tresorbestand auf 237.044.421 erh枚ht. Die ausstehenden Aktien (ohne Tresorbestand) belaufen sich nun auf 4.078.340.989 und bilden die neue Basis f眉r die Offenlegung der Stimmrechte. Der Tresorbestand entspricht 5,81 % der Gesamtstimmrechte.

Es wurden keine operativen, Ergebnis- oder Prognoseaktualisierungen bereitgestellt; die Einreichung dient haupts盲chlich der Erf眉llung der Offenlegungspflichten gem盲脽 UK DTR 5.5.1R.

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
 
 
For the month of August 2025
 
Commission File Number 001-15170
 
 
GSK plc
(Translation of registrant's name into English)
 
 
79 New Oxford Street, London, WC1A 1DG
(Address of principal executive office)
 
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
 
 
 Transaction in own shares
 
GSK plc (the "Company") announces today acting through its corporate stockbroker, Merrill Lynch International (the "Broker"), it has purchased the following number of the Company's ordinary shares of 31¼ pence each.
 
Date of purchase:
 
31 July 2025
 
Aggregate number of ordinary shares of 31¼ pence each purchased:
 
474,100
 
Lowest price paid per share (GBp):
 
1,404.50p
 
Highest price paid per share (GBp):
 
1,461.00p
 
Volume-weighted average price paid per share (GBp):
 
1,423.11p
 
 
The purchased shares will be held as Treasury shares.
 
Such purchase forms part of the Company's existing buyback programme and was effected pursuant to the non-discretionary agreement entered into with the Broker on 4 June 2025, as announced on 4 June 2025. Since 4 June 2025 the Company has purchased 18,910,038 ordinary shares.
 
Following the above purchase, the Company will hold 237,044,421 ordinary shares in treasury and have 4,078,340,989 ordinary shares in issue (excluding Treasury shares).
 
The total number of voting rights in the Company is 4,078,340,989. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
 
The Company confirms that, in accordance with DTR 5.5.1R, following the above purchase the percentage of voting rights attributable to the ordinary shares held in treasury is 5.81 per cent.
 
Detailed information of the individual trades made by the Broker on the London Stock Exchange and the CBOE Europe Limited recognised investment exchange (through its order books having market identification codes CHIX or BATE) as part of the buyback programme can be found at:
                       
http://www.rns-pdf.londonstockexchange.com/rns/5000T_1-2025-7-31.pdf
 
 
Ends
 
 
GSK enquiries
 
 
 
 
Media:
 
Tim Foley
 
+44 (0) 20 8047 5502
 
(London)
 
 
Kathleen Quinn
 
+1 202 603 5003
 
(Washington DC)
 
 
 
 
 
Investor Relations:
 
Constantin Fest
 
+44 (0) 7831 826525
 
(London)
 
 
James Dodwell
 
+44 (0) 20 8047 2406
 
(London)
 
 
Mick Readey
 
+44 (0) 7990 339653
 
(London)
 
 
Steph Mountifield
 
+44 (0) 7796 707505
 
(London)
 
 
Jeff McLaughlin
 
+1 215 751 7002
 
(Philadelphia)
 
 
Frannie DeFranco
 
+1 215 751 3126
 
(Philadelphia)
 

Cautionary statement regarding forward-looking statements
 
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2024, and GSK's Q1 Results for 2025.

Registered in England & Wales:
No. 3888792
 
Registered Office:
79 New Oxford Street
London
WC1A 1DG
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 
GSK plc
 
(Registrant)
 
 
Date: August 01, 2025
 
 
 
 
By:/s/ VICTORIA WHYTE
--------------------------
 
 
 
Victoria Whyte
 
Authorised Signatory for and on
 
behalf of GSK plc

Source:

FAQ

How many GSK shares were repurchased on 31 July 2025?

GSK bought 474,100 ordinary shares.

What was the average price paid per share?

The volume-weighted average price was 1,423.11 GBp.

How many shares has GSK repurchased since 4 June 2025?

A total of 18,910,038 shares have been bought back under the programme.

What is GSK鈥檚 current share count excluding treasury shares?

Shares in issue now stand at 4,078,340,989.

What percentage of voting rights is held in treasury?

Post-transaction, treasury stock represents 5.81 % of total voting rights.

Will the repurchased shares be cancelled?

No, the shares will be held as treasury shares for potential future use.
Stock GSK logo
GSK PLC

NYSE:GSK

GSK Rankings

#219 Ranked by Market Cap
#731 Ranked by Dividends

GSK Latest News

Jul 27, 2025
Hengrui Pharma and GSK enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
Jul 24, 2025
GSK sponsors 2025 National Senior Games as part of Sideline RSV campaign to raise awareness of RSV in older adults
Jul 17, 2025
US FDA Approves GSK鈥檚 SHINGRIX in a Prefilled Syringe Presentation
Jul 10, 2025
GSK begins shipping influenza vaccine doses for the 2025-26 flu season
Jun 24, 2025
FDA approves Benlysta (belimumab) Autoinjector for children with active lupus nephritis

GSK Latest SEC Filings

Aug 1, 2025
[6-K] GSK plc American Current Report (Foreign Issuer)
Jul 31, 2025
[6-K] GSK plc American Current Report (Foreign Issuer)
Jul 30, 2025
[6-K] GSK plc American Current Report (Foreign Issuer)
Jul 30, 2025
[6-K] GSK plc American Current Report (Foreign Issuer)
Jul 29, 2025
[6-K] GSK plc American Current Report (Foreign Issuer)

GSK Stock Data

78.63B
2.04B
0.06%
17.05%
0.91%
Drug Manufacturers - General
Healthcare
United Kingdom
England